Development of a novel multiplex in vitro binding assay to profile p53-DNA interactions

Cell Cycle

Volumn 9, Issue 15, 2010, Pages 3102-3110

  Goh, Walter ^a   Lane, David ^a   Ghadessy, Farid ^a  

^a p53 Laboratory   (Singapore)

Author keywords

DNA binding assay; In vitro; Multiplex; p53; Tumor suppressor

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL FATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA BINDING; DNA RESPONSIVE ELEMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS;

EID: 77956853383     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.15.12436     Document Type: Article

References (44)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458:1127-30.
3. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73.
4. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-101. (Pubitemid 350248530)
5. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010-4. (Pubitemid 38209704)
6. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12. (Pubitemid 351574202)
7. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9:724-37.
8. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55. (Pubitemid 24259959)
9. McLure KG, Lee PW. How p53 binds DNA as a tetramer. EMBO J 1998; 17:3342-50.
10. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell 2006; 22:741-53.
11. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68-76.
12. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007; 28:289-98.
13. Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000; 19:1245-56.
14. Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007; 26:2243-54.
15. Veprintsev DB, Fersht AR. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 2008; 36:1589-98.
16. Fried M, Crothers DM. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. Nucleic Acids Res 1981; 9:6505-25.
17. Galas DJ, Schmitz A. DNAse footprinting: a simple method for the detection of protein-DNA binding specificity. Nucleic Acids Res 1978; 5:3157-70.
18. Jagelska E, Brazda V, Pospisilova S, Vojtesek B, Palecek E. New ELISA technique for analysis of p53 protein/ DNA binding properties. J Immunol Methods 2002; 267:227-35.
19. Noureddine MA, Menendez D, Campbell MR, Bandele OJ, Horvath MM, Wang X, et al. Probing the functional impact of sequence variation on p53-DNA interactions using a novel microsphere assay for protein-DNA binding with human cell extracts. PLoS Genet 2009; 5:1000462.
20. Maillart E, Brengel-Pesce K, Capela D, Roget A, Livache T, Canva M, et al. Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction. Oncogene 2004; 23:5543-50.
21. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR. Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol 2005; 348:589-96.
22. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3:632-8.
23. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol 2010; 17:46-56.
24. Fen CX, Coomber DW, Lane DP, Ghadessy FJ. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization. J Mol Biol 2007; 371:1238-48.
25. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, et al. Cell-free translation reconstituted with purified components. Nat Biotechnol 2001; 19:751-5.
26. Hupp TR, Lane DP. Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harb Symp Quant Biol 1994; 59:195-206.
27. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.
28. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9:935-44.
29. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7:683-94.
30. Natan E, Hirschberg D, Morgner N, Robinson CV, Fersht AR. Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci USA 2009; 106:14327-32.
31. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol 1998; 8:369-78.
32. Yakovleva T, Pramanik A, Kawasaki T, Tan-No K, Gileva I, Lindegren H, et al. p53 Latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences. J Biol Chem 2001; 276:15650-8.
33. Weinberg RL, Freund SM, Veprintsev DB, Bycroft M, Fersht AR. Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol 2004; 342:801-11.
34. Fojta M, Pivonkova H, Brazdova M, Nemcova K, Palecek J, Vojtesek B. Investigations of the supercoil-selective DNA binding of wild type p53 suggest a novel mechanism for controlling p53 function. Eur J Biochem 2004; 271:3865-76.
35. Nagaich AK, Appella E, Harrington RE. DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J Biol Chem 1997; 272:14842-9.
36. Urano T, Nishimori H, Han H, Furuhata T, Kimura Y, Nakamura Y, et al. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. Cancer Res 1997; 57:3281-7.
37. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992; 358:83-6.
38. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 2003; 100:13303-7.
39. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-13.
40. Rolley N, Butcher S, Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene 1995; 11:763-70.
41. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecularweight compound. Nat Med 2002; 8:282-8.
42. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 2008; 105:10360-5.
43. Bell S, Klein C, Muller L, Hansen S, Buchner J. p53 contains large unstructured regions in its native state. J Mol Biol 2002; 322:917-27.
44. Das S, Boswell SA, Aaronson SA, Lee SW. p53 promoter selection: choosing between life and death. Cell Cycle 2008; 7:154-7.